Nektar Therapeutics (NKTR) Competitors $0.93 -0.01 (-1.35%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NKTR vs. OMER, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTSShould you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry. Nektar Therapeutics vs. Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Nektar Therapeutics (NASDAQ:NKTR) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership. Is NKTR or OMER more profitable? Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -180.70%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-180.70% -173.28% -46.31% Omeros N/A N/A -49.92% Does the MarketBeat Community favor NKTR or OMER? Omeros received 112 more outperform votes than Nektar Therapeutics when rated by MarketBeat users. Likewise, 71.03% of users gave Omeros an outperform vote while only 70.74% of users gave Nektar Therapeutics an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes63170.74% Underperform Votes26129.26% OmerosOutperform Votes74371.03% Underperform Votes30328.97% Does the media refer more to NKTR or OMER? In the previous week, Omeros had 3 more articles in the media than Nektar Therapeutics. MarketBeat recorded 12 mentions for Omeros and 9 mentions for Nektar Therapeutics. Omeros' average media sentiment score of 0.88 beat Nektar Therapeutics' score of 0.67 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 6 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of NKTR or OMER? 75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 3.7% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings and valuation, NKTR or OMER? Omeros has lower revenue, but higher earnings than Nektar Therapeutics. Omeros is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$93.14M1.84-$276.06M-$0.84-1.11OmerosN/AN/A-$117.81M-$2.31-4.46 Do analysts prefer NKTR or OMER? Nektar Therapeutics presently has a consensus target price of $4.10, indicating a potential upside of 341.67%. Omeros has a consensus target price of $9.00, indicating a potential downside of 12.71%. Given Nektar Therapeutics' higher probable upside, research analysts plainly believe Nektar Therapeutics is more favorable than Omeros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Omeros 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more volatility & risk, NKTR or OMER? Nektar Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. SummaryOmeros beats Nektar Therapeutics on 11 of the 18 factors compared between the two stocks. Ad DarwinHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTR vs. The Competition Export to ExcelMetricNektar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$171.23M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.1110.5991.3417.19Price / Sales1.84195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book1.355.104.794.78Net Income-$276.06M$151.51M$120.07M$225.60M7 Day Performance-8.09%-2.14%-1.90%-1.24%1 Month Performance-8.09%-3.13%11.43%3.06%1 Year Performance96.67%11.51%30.59%16.50% Nektar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTRNektar Therapeutics4.3607 of 5 stars$0.93-1.3%$4.10+341.7%+95.6%$171.23M$93.14M-1.11220News CoverageGap UpOMEROmeros2.7162 of 5 stars$7.82+2.5%$9.00+15.1%+244.8%$453.17MN/A0.00198Analyst ForecastNews CoverageASMBAssembly Biosciences3.8138 of 5 stars$15.50+0.8%$35.00+125.8%+64.6%$98.52M$28.33M0.00100News CoverageCPIXCumberland Pharmaceuticals0.3289 of 5 stars$2.23-6.3%N/A+30.5%$31.31M$36.79M-2.8380Analyst ForecastNews CoverageGap DownLLYEli Lilly and Company4.9956 of 5 stars$779.49-1.2%$1,002.22+28.6%+34.6%$739.98B$40.86B85.4843,000Gap UpJNJJohnson & Johnson4.8925 of 5 stars$145.24-0.9%$174.73+20.3%-5.7%$349.68B$87.70B21.22131,900ABBVAbbVie4.9353 of 5 stars$172.21-0.7%$203.65+18.3%+15.7%$304.32B$55.53B60.2350,000Analyst ForecastInsider TradeMRKMerck & Co., Inc.4.989 of 5 stars$100.99-0.2%$129.20+27.9%-6.9%$255.47B$60.12B21.3172,000Analyst DowngradePFEPfizer4.9831 of 5 stars$25.48-0.4%$32.15+26.2%-4.6%$144.39B$58.50B34.7688,000Analyst ForecastOptions VolumeAnalyst RevisionBMYBristol-Myers Squibb4.7866 of 5 stars$56.29+0.9%$55.64-1.1%+12.5%$114.17B$47.44B-15.5434,100ZTSZoetis4.6049 of 5 stars$177.48-0.4%$216.70+22.1%-15.3%$80.07B$8.54B33.4914,100 Related Companies and Tools Related Companies OMER Competitors ASMB Competitors CPIX Competitors LLY Competitors JNJ Competitors ABBV Competitors MRK Competitors PFE Competitors BMY Competitors ZTS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NKTR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTR Stock Alerts